1,3-diaryl-2-propenones and 2-benzylidene-1,3-indandiones: a quest for compounds displaying greater toxicity to neoplasms than normal cells.
A series of 1,3-diaryl-2-propenones 2a-j and analogous 2-benzylidene-1,3-indandiones 3a-j were evaluated against various neoplasms and normal cells. In general, greater cytotoxic potencies and selective toxicity to human malignant cells were observed by the compounds in series 2 rather than 3. In particular, 2i emerged as a lead molecule having an average CC(50) figure of 8.6 µM and a selective index value of 18. Various physicochemical features of 2a-j were correlated with the cytotoxic potencies to neoplastic cell lines which provide guidelines for expansion of this series of compounds. The enone 2i induced internucleosomal DNA fragmentation and activated caspase-3 in HL-60 cells suggesting that one of the ways in which the cytotoxicity of the compounds in series 2 is mediated towards some of the cell lines used in this study is by apoptosis. Neurotoxicity in mice was generally lower in series 2 than 3a-j.
Pati
Hari N
HN
Drug Design and Discovery Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Das
Umashankar
U
Sakagami
Hiroshi
H
Kawase
Masame
M
Chu
Qing
Q
Wang
Qintao
Q
Stables
James P
JP
Dimmock
Jonathan R
JR
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000187:drug effects / Q000378:metabolism; D002460:Cell Line; D045744:Cell Line, Tumor; D047188:Chalcones / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D053938:DNA Fragmentation / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D007189:Indans / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D020258:Neurotoxicity Syndromes / Q000209:etiology; D021281:Quantitative Structure-Activity Relationship; D051381:Rats
D000970:Antineoplastic Agents; D047188:Chalcones; D007189:Indans; D053148:Caspase 3
Anticancer Agents Med Chem. 2009 Mar;9(3):336-47
19275525
Curr Pharm Des. 2005;11(13):1679-93
15892668
Nature. 2005 Oct 13;437(7061):942-3
16222266
Curr Med Chem. 1999 Dec;6(12):1125-49
10519918
J Am Pharm Assoc Am Pharm Assoc. 1957 Mar;46(3):208-9
13502156
J Enzyme Inhib Med Chem. 2004 Aug;19(4):303-12
15558945
Bioorg Med Chem. 2010 Feb;18(3):1364-70
20064725
Phytother Res. 2003 Apr;17(4):348-52
12722138
Mini Rev Med Chem. 2007 Feb;7(2):131-9
17305587
Curr Drug Targets. 2009 Apr;10(4):363-71
19355861
J Med Chem. 2002 Jul 4;45(14):3103-11
12086496
Pharmazie. 2003 Apr;58(4):227-32
12749401
Fundam Appl Toxicol. 1986 Feb;6(2):270-7
3699317
J Med Chem. 1999 Apr 22;42(8):1358-66
10212121
J Enzyme Inhib Med Chem. 2007 Feb;22(1):37-42
17373545
Anticancer Res. 2007 Jan-Feb;27(1A):133-43
17352225
Phytother Res. 2004 Mar;18(3):212-23
15103668
Curr Med Chem. 2005;12(4):481-99
15720256
Pharmacol Res. 2008 Apr;57(4):259-65
18387817
Anticancer Agents Med Chem. 2007 Jan;7(1):55-73
17266505
Bioorg Med Chem. 2007 May 15;15(10):3373-80
17383883